Systematic Review: Opioid Treatment for Chronic Back Pain: Prevalence, Efficacy, and Association with Addiction

  1. Bridget A. Martell, MD, MA;
  2. Patrick G. O'Connor, MD, MPH;
  3. Robert D. Kerns, PhD;
  4. William C. Becker, MD;
  5. Knashawn H. Morales, ScD;
  6. Thomas R. Kosten, MD; and
  7. David A. Fiellin, MD
  1. From Yale University School of Medicine, New Haven, Connecticut; VA Connecticut Health Care System, West Haven, Connecticut; and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

    Abstract

    Background: The prevalence, efficacy, and risk for addiction for persons receiving opioids for chronic back pain are unclear.

    Purpose: To determine the prevalence of opioid treatment, whether opioid medications are effective, and the prevalence of substance use disorders among patients receiving opioid medications for chronic back pain.

    Data Sources: English-language studies from MEDLINE (1966–March 2005), EMBASE (1966–March 2005), Cochrane Central Register of Controlled Clinical Trials (to 4th quarter 2004), PsychInfo (1966–March 2005), and retrieved references.

    Study Selection: Articles that studied an adult, nonobstetric sample; used oral, topical, or transdermal opioids; and focused on treatment for chronic back pain.

    Data Extraction: Two investigators independently extracted data and determined study quality.

    Data Synthesis: Opioid prescribing varied by treatment setting (range, 3% to 66%). Meta-analysis of the 4 studies assessing the efficacy of opioids compared with placebo or a nonopioid control did not show reduced pain with opioids (g, −0.199 composite standardized mean difference [95% CI, −0.49 to 0.11]; P = 0.136). Meta-analysis of the 5 studies directly comparing the efficacy of different opioids demonstrated a nonsignificant reduction in pain from baseline (g, −0.93 composite standardized mean difference [CI, −1.89 to −0.03]; P = 0.055). The prevalence of lifetime substance use disorders ranged from 36% to 56%, and the estimates of the prevalence of current substance use disorders were as high as 43%. Aberrant medication-taking behaviors ranged from 5% to 24%.

    Limitations: Retrieval and publication biases and poor study quality. No trial evaluating the efficacy of opioids was longer than 16 weeks.

    Conclusions: Opioids are commonly prescribed for chronic back pain and may be efficacious for short-term pain relief. Long-term efficacy (≥16 weeks) is unclear. Substance use disorders are common in patients taking opioids for back pain, and aberrant medication-taking behaviors occur in up to 24% of cases.

    Article and Author Information

    • Grant Support: Dr. Martell was supported by a Veterans Administration Career Development Award during the conduct of this study.

    • Potential Financial Conflicts of Interest: None disclosed.

    • Requests for Single Reprints: David A. Fiellin, MD, Yale University, 333 Cedar Street, PO Box 208025, New Haven, CT 06520-8025; e-mail, david.fiellin{at}yale.edu.

    • Current Author Addresses: Dr. Martell: Pfizer, New Haven Clinical Research Unit, 50 Pequot Avenue, Mailstop 3000, New London, CT 06330.

    • Drs. Kerns and Kosten: VA Connecticut Health Care System, Psychology Service, 116B, 950 Campbell Avenue, West Haven, CT 06516.

    • Dr. Morales: Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, 626 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021.

    • Drs. Fiellin, O'Connor, and Becker: Yale University, 333 Cedar Street, PO Box 208025, New Haven, CT 06520-8025.

    Responses to this article

    « Previous | Next Article »Table of Contents